Dtsch Med Wochenschr 2020; 145(03): 146-150
DOI: 10.1055/a-0955-9587
Klinischer Fortschritt
Geriatrie
© Georg Thieme Verlag KG Stuttgart · New York

Präventive Geriatrie: kognitiven Abbau verhindern

Strategies to prevent age-related cognitive decline
Anna Maria Meyer*
1   Klinische Altersforschung, Klinik II für Innere Medizin und Zentrum für Molekulare Medizin, Uniklinik Köln
,
Natalie Podolski*
1   Klinische Altersforschung, Klinik II für Innere Medizin und Zentrum für Molekulare Medizin, Uniklinik Köln
,
Lena Pickert*
1   Klinische Altersforschung, Klinik II für Innere Medizin und Zentrum für Molekulare Medizin, Uniklinik Köln
,
Maria Cristina Polidori
1   Klinische Altersforschung, Klinik II für Innere Medizin und Zentrum für Molekulare Medizin, Uniklinik Köln
2   CECAD, Universität zu Köln, Medizinische Fakultät und Uniklinik Köln
› Author Affiliations
Further Information

Publication History

Publication Date:
04 February 2020 (online)

Was ist neu?

Prävention des kognitiven Abbaus Maßnahmen zur Früherkennung und zur Prävention des kognitiven Abbaus stehen im Vordergrund der Therapie. Im Gegensatz zur früheren Trennung zwischen neurodegenerativen und vaskulären Formen der Demenz wird aktuell die konsequente Therapie und Einstellung von kardiovaskulären Risikofaktoren angestrebt, um das Fortschreiten von möglicherweise allen Demenzformen zu verlangsamen. Die im Mai dieses Jahres von der Weltgesundheitsorganisation veröffentlichten Leitlinien geben Anhaltspunkte, wie dem Nachlassen der kognitiven Funktion mit zunehmendem Alter begegnet werden kann. Zu den Säulen der Prävention gehören eine ausgewogene Ernährung (für die Substitution einzelner, künstlicher Nährstoffe gibt es keine Evidenz), körperliche Aktivität (vor allem aerobes Training), ausreichender Schlaf, Konvivialität und soziale Interaktion (sensorische Störungen, gerade eine Beeinträchtigung des Hörens, dürfen nicht unterschätzt werden) sowie kognitive Aktivitäten und Übungen, die die allgemeinen, exekutiven und logischen Funktionen, die Denkgeschwindigkeit und das Arbeitsgedächtnis unterstützen.

Konsequenz für den klinischen Alltag Obwohl alle o. g. Bereiche des Lebensstils für die Prävention des kognitiven Abbaus wichtig sind, sind multidimensionale Interventionen nur dann für den Erhalt der Funktionen wirksam, wenn diese

  • auf die Bedürfnisse jedes einzelnen Patienten zugeschnitten werden (die sogenannten personalized tailored interventions) und

  • mit persönlichem Interesse, guter Lebensqualität und adäquatem Wohlbefinden verbunden sind.

Abstract

The increasing aging demographics never seen before is associated with the enormous challenge of dementia epidemics which urgently needs a paradigm shift in the approach to cognitive functions in health and disease. If on one hand the achievement or maintenance of a healthy lifestyle should be a medical priority, the early recognition of cognitive disturbances is mandatory. Cognitive impairment is not only associated with disability and lack of compliance and adherence, but also with dangerous geriatric syndromes such as instability, falls, and delirium. The evaluation of cognitive performance, particularly in older patients and especially in those hospitalized for other reasons, should be performed in all cases. While the National Institute of Aging and Alzheimer Association established new criteria for the diagnosis of Alzheimer’s disease, the large majority of dementia cases are assigned to a multifactorial syndrome presenting as a long-lasting continuum from organ/function integrity to dementia. While the monoclonal antibody aducanumab is under careful evaluation for release on the market as the first curative drug, current anti-Alzheimer medication strategies remain symptomatic. In spite of the previous distinction between neurodegenerative and vascular forms of dementia, it is now accepted that control of vascular risk factors and comorbidities strongly affects the prevention of all types of cognitive impairment. The WHO has published in May 2019 an official guideline document for reducing dementia risk. The guidelines provide recommendations on the major modifiable lifestyle factors and chronic diseases. The best way to prevent cognitive impairment and its worsening include vascular risk control and a healthy diet including a balanced natural nutrition (without nutritional supplements for which scientific evidence is lacking), physical exercise (preferably aerobic), enough social participation, interaction and conviviality as well as cognitive exercise (focusing on general cognitive function, executive function and working memory) While the activation of all domains of lifestyle are critical for the achievement of the best preventive effects, these should be implemented 1) in a personalized, goal-oriented fashion (the so called tailored interventions) and 2) with the ultimate goal of maintaining the care of personal interests and functions along with quality of life and wellbeing.

For an effective prevention of cognitive decline, resources from all domains of lifestyle (nutrition, exercise, rest, social participation, cognitive activity) should be used, however in a personalized way. The Comprehensive Geriatric Assessment (CGA), evaluating the physical, psychosocial and functional aspects of young-old, old-old and oldest-old persons, can be used to detect early cognitive impairment and factors associated with its course in order to modulate them.

* Equal contributors.


 
  • Literatur

  • 1 Winblad B, Amouyel P, Andrieu S. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15: 455-532 . doi:10.1016/s1474-4422(16)00062-4
  • 2 Polidori MC. Comprehensive Geriatric Assessment in Patients with Cognitive Decline. In: Pilotto A, Martin F. eds. Comprehensive Geriatric Assessment. Practical Issues in Geriatrics. Berlin: Springer; 2018
  • 3 Jack CR, Bennett DA, Blennow K. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14: 535-562 . doi:10.1016/j.jalz.2018.02.018
  • 4 Polidori MC. Lifestyle strategies in cognitive decline: Focus on nutrition. Special Issue of Nutrients 2019 11(4)
  • 5 WHO. Risk reduction of cognitive decline and dementia. WHO guidelines. WHO Guidelines. Genf: WHO; 2019
  • 6 Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde. S3-Leitlinie „Demenzen“. Im Internet: https://www.awmf.org/uploads/tx_szleitlinien/038-013l_S3-Demenzen-2016-07.pdf Stand: 3.12.2019
  • 7 Chen X, Maguire B, Brodaty H. et al. Dietary Patterns and Cognitive Health in Older Adults: A Systematic Review. J Alzheimers Dis 2019; 67: 583-619 . doi:10.3233/JAD-180468
  • 8 Polidori MC. Dementia. In: Rattan S. ed. Encyclopedia of Biomedical Gerontology. Cambridge, MA: Elsevier Academic Press; 2019
  • 9 Gerger P, Pai RK, Stuckenschneider T. et al. Associations of Lipophilic Micronutrients with Physical and Cognitive Fitness in Persons with Mild Cognitive Impairment. Nutrients 2019; 11: E902 . doi:10.3390/nu11040902
  • 10 Xie L, Kang H, Xu Q. et al. Sleep drives metabolic clearance from adult brain. Science 2013; 342: 373-377
  • 11 Lim ASP, Gaiteri C, Yu L. et al. Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts. PLoS Med 2018; 15: e1002647
  • 12 Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. JAMA 2019; 322: 1589-1599 . doi:10.1001/jama.2019.4782
  • 13 Schlegel P, Novotny M, Klimova B. et al. „Muscle-Gut-Brain Axis“: Can Physical Activity Help Patients with Alzheimer’s Disease Due to Microbiome Modulation?. J Alzheimers Dis 2019; 71: 861-878 . doi:10.3233/jad-190460
  • 14 Trigiani LJ, Hamel E. An endothelial link between the benefits of physical exercise in dementia. J Cereb Blood Flow Metab 2017; 37: 2649-2664 . doi:10.1177/0271678x17714655
  • 15 Völter C, Götze L, Bruene-Cohrs U. et al. Hearing and cognition: neurocognitive test batteries in otorhinolaryngology. HNO 2019; Oct 18. DOI: 10.1007/s00106-019-00762-7.
  • 16 Jaeggi SM, Buschkuehl M, Jonides J. et al. Short- and long-term benefits of cognitive training. Proc Natl Acad Sci U S A 2011; 108: 10081-10086 . doi:10.1073/pnas.1103228108
  • 17 Chiu HL, Chu H, Tsai JC. et al. The effect of cognitive-based training for the healthy older people: A meta-analysis of randomized controlled trials. PLoS One 2017; 12: e0176742 . doi:10.1371/journal.pone.0176742
  • 18 Kallio EL, Öhman H, Hietanen M. et al. Effects of Cognitive Training on Cognition and Quality of Life of older Persons with dementia. J Am Geriatr Soc 2018; 66: 664-670 . doi:10.111/jgs.15196
  • 19 Roheger M, Kessler J, Kalbe E. Structured Cognitive Training Yields Best Results in Healthy Older Adults, and Their ApoE4 State and Baseline Cognitive Level Predict Training Benefits. Cogn Behav Neurol 2019; 32: 76-86 . doi:10.1097/WMN.0000000000000195
  • 20 Lumsden J, Edwards EA, Lawrence NS. et al. Gamification of Cognitive Assessment and Cognitive Training: A Systematic Review of Applications and Efficacy. JMIR Serious Games 2016; 4: e11 . doi:10.2196/games.5888
  • 21 Baller G, Kalbe E, Kaesberg S. et al. NEUROvitalis. Neuropsychologisches Gruppentraining. Köln: Prolog; 2009
  • 22 Ngandu T, Lehtisalo J, Solomon A. et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 385: 2255-2263 . doi:10.1016/s0140-6736(15)60461-5
  • 23 Marengoni A, Rizzuto D, Fratiglioni L. et al. The Effect of a 2-Year Intervention Consisting of Diet, Physical Exercise, Cognitive Training, and Monitoring of Vascular Risk on Chronic Morbidity-the FINGER Randomized Controlled Trial. J Am Med Dir Assoc 2018; 19: 355-360 e351. doi:10.1016/j.jamda.2017.09.020
  • 24 Andrieu S, Cantet C, Bonnefoy M. et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 2017; 16: 377-389 . doi:10.1016/s1474-4422(17)30040-6